Could a new scan unlock better breast cancer treatment?

NCT ID NCT06732336

Recruiting now Diagnosis Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special PET scan using a radioactive tracer called 89Zr-trastuzumab to find low levels of HER2 in metastatic breast cancer. Researchers aim to see if this scan can better detect tumors that might respond to newer drugs like Enhertu. The trial will involve 40 adults with HER2-low breast cancer, and results could help personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-trastuzumab (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could help doctors see which tumors have low HER2, guiding personalized treatments like Enhertu for more patients.
What could go wrong: This is an early-phase trial with only 40 participants, so results may not apply broadly. The imaging may not reliably detect all low-HER2 tumors, and there are no direct treatment benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC

Contacts and locations

Locations

Centre de recherche du CHUS
RECRUITING

Sherbrooke, Quebec, J1H5N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.